Freeline Announces June 2022 Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 01, 2022 16:01 ET
|
Freeline Therapeutics
LONDON, July 01, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on June 30, 2022, the Company granted a newly hired employee non-statutory options to...
Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress
June 24, 2022 09:32 ET
|
Freeline Therapeutics
LONDON, June 24, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the upcoming presentation of new and important clinical data for its AAVS3-based gene...
Freeline Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B
June 14, 2022 07:00 ET
|
Freeline Therapeutics
Initial cohort one data suggest predictable and sustained Factor IX normalization, supporting additional dosing at the same low dose with the same optimized, prophylactic immune management regimen ...
Freeline Announces May 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 03, 2022 16:02 ET
|
Freeline Therapeutics
LONDON, June 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on May 31, 2022, the Company granted its newly hired Chief Financial Officer, Paul...
Freeline Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
June 03, 2022 16:01 ET
|
Freeline Therapeutics
LONDON, June 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today disclosed the receipt of a notice (the “Notice”) on May 31, 2022 from...
Freeline Reports First Quarter 2022 Financial Results and Business Highlights
May 10, 2022 16:01 ET
|
Freeline Therapeutics
Phase 1/2 clinical programs in Hemophilia B, Gaucher disease and Fabry disease on track to deliver 2022 milestones Recent appointment of new Chief Financial Officer further strengthens leadership...
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2022 16:01 ET
|
Freeline Therapeutics
LONDON, May 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that on April 29, 2022, the Company granted five newly hired...
Freeline To Present at the 25th Annual Meeting of the American Society of Gene and Cell Therapy
May 02, 2022 17:10 ET
|
Freeline Therapeutics
LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced the upcoming presentation of five posters at the 25th Annual...
Freeline Appoints Paul Schneider as Chief Financial Officer
April 19, 2022 08:01 ET
|
Freeline Therapeutics
LONDON, April 19, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that Paul M. Schneider has been appointed Chief Financial...
Freeline Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2022 16:01 ET
|
Freeline Therapeutics
LONDON, April 04, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that on March 31, 2022, the Company granted its newly hired...